Gilead Sciences Inc (GILD) Stock Analysis

Sector: HEALTHCARE - DRUG MANUFACTURERS - GENERAL

Exchange: NASDAQ

Key Metrics

• Price: $143.77
• Market Cap: $182.53B
• P/E Ratio: 21.70
• EPS: $6.78
• Dividend Yield: 0.02%
• 52-Week High: $157.29
• 52-Week Low: $91.47

Market Sentiment

Gilead Sciences Inc currently has a Bullish sentiment score of 0.26.

About Gilead Sciences Inc

Gilead Sciences, Inc. is a prominent biopharmaceutical company headquartered in Foster City, California, specializing in the research, development, and commercialization of innovative antiviral therapies targeting infectious diseases, including HIV and hepatitis. Its flagship products, such as Harvoni and Sovaldi, have significantly advanced treatment protocols for chronic hepatitis C, highlighting Gilead's leadership in the field. Emphasizing its commitment to addressing unmet medical needs,...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Gilead Sciences Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

What is GILD's current dividend yield?

Gilead Sciences Inc (GILD) has a current dividend yield of 0.02%.

Does GILD pay dividends?

Yes, Gilead Sciences Inc pays dividends with a current yield of 0.02%.

What is GILD's P/E ratio?

Gilead Sciences Inc has a price-to-earnings (P/E) ratio of 21.70.

What is GILD's market cap?

Gilead Sciences Inc (GILD) has a market capitalization of $182.53B with a current stock price of $143.77.